BioCentury
ARTICLE | Management Tracks

Tolstrup stepping up at Lundbeck

Plus: Neomorph, Becton Dickinson, Karuna, Ascentage and Hummingbird

November 30, 2021 2:28 AM UTC

H. Lundbeck A/S (CSE:LUN) promoted EVP for Commercial Operations Jacob Tolstrup to chief commercial officer, effective Jan. 1, as Peter Anastasiou readies to pursue another opportunity. Tolstrup has been at Lundbeck for more than two decades, on the company’s executive committee for one, and has been an EVP for four years. He is also chairman of Pharmacosmos A/S. 

Philip Chamberlain became CEO at San Diego-based Neomorph Inc., a Deerfield Management portfolio company that he co-founded. Chamberlain was an executive director at Celgene Corp. for 12 years, where he led its structural and chemical biology department and where he was responsible for discoveries related to the mechanism of action of thalidomide analogs as prototype molecular glues. Neomorph is developing targeted protein degradation therapies using molecular glues for undruggable targets...